Cart
sales@molnova.com
Bisindolylmaleimide VIII acetate
CAS No. 138516-31-1
Bisindolylmaleimide VIII acetate( Ro 31-7549 acetate | Bis VIII acetate )
Catalog No. M23542 CAS No. 138516-31-1
Bisindolylmaleimide VIII acetate is a potent and selective PKC inhibitor (IC50: 158 nM for rat brain PKC).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 129 | In Stock |
|
| 5MG | 89 | In Stock |
|
| 10MG | 142 | In Stock |
|
| 25MG | 297 | In Stock |
|
| 50MG | 423 | In Stock |
|
| 100MG | 591 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBisindolylmaleimide VIII acetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionBisindolylmaleimide VIII acetate is a potent and selective PKC inhibitor (IC50: 158 nM for rat brain PKC).
-
DescriptionBisindolylmaleimide VIII acetate is a potent and selective PKC inhibitor (IC50: 158 nM for rat brain PKC). It has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively.
-
In VitroBisindolylmaleimide VIII acetate (Ro 31-7549 acetate; 5 μM; 8, 12 hours) dramatically increases TRA-8-induced cell death in time-dependent and TRA-8 dose-dependent manners. Bisindolylmaleimide VIII acetate (5 μM; 6 hours) significantly decreases procaspase-8 at 4 h and completely disappeares at 6 h after the combined treatment with TRA-8. Apoptosis Analysis Cell Line:1321N1 cells Concentration:5 μM Incubation Time:8, 12 hours Result: Dramatically increased TRA-8-induced cell death in time-dependent and TRA-8 dose-dependent manners.Western Blot Analysis Cell Line:1321N1 cells Concentration:5 μM Incubation Time:6 hours Result:Significantly decreased procaspase-8 at 4 h and completely disappeared at 6 h.
-
In VivoBisindolylmaleimide VIII acetate (Ro 31-7549 acetate; 100 μg; IP; every other day for three doses) results in nearly complete tumor regression combined toTRA-8. The treatment with Bisindolylmaleimide VIII acetate alone does not induce significant tumor regression. Animal Model:6-8-week-old female NOD/SCID mice. Dosage:100 μg Administration:IP; every other day for three doses Result:Resulted in nearly complete tumor regression combined toTRA-8.
-
SynonymsRo 31-7549 acetate | Bis VIII acetate
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|PKC|PKCα|PKCβ1|PKCβ2|PKCγ|PKCε
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number138516-31-1
-
Formula Weight458.51
-
Molecular FormulaC26H26N4O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (545.24 mM)
-
SMILESO=C(C(C1=CN(CCCN)C2=C1C=CC=C2)=C3C4=CN(C)C5=C4C=CC=C5)NC3=O.CC(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Kinsenoside;(+)-Kins...
Kinsenoside shows significant antihepatotoxic and anti-inflammatory activities. Kinsenoside could be useful for repairing beta cells in pancreatic islet injury as well as improving its function it could promote the glucose tolerance of acute glucose increase in both diabetic and normal healthy rats.
-
DT2216
DT2216 inhibits various Bcl-XL-dependent leukemias and cancer cells, but is significantly less toxic to platelets.DT2216 is a selective B-cell lymphoma, extremely large (BCL-XL), proteolytic targeting chimera (PROTAC).
-
Vitamin E succinate
Vitamin E succinate (D-alpha-Tocopherol Succinate) is an antioxidant tocopherol that belongs to the vitamin E class of compounds Vitamin E succinate has antitumor activity, induces apoptosis, and is used as an adjuvant in the treatment of cancer and in the synthesis of INVITE, a biocoupling compound.
